These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 28579852)
1. Treatment of Myelofibrosis: Old and New Strategies. Iurlo A; Cattaneo D Clin Med Insights Blood Disord; 2017; 10():1179545X17695233. PubMed ID: 28579852 [TBL] [Abstract][Full Text] [Related]
2. State-of-the-Art Review on Myelofibrosis Therapies. Wang F; Qiu T; Wang H; Yang Q Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489 [TBL] [Abstract][Full Text] [Related]
3. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Mughal TI; Vaddi K; Sarlis NJ; Verstovsek S Int J Gen Med; 2014; 7():89-101. PubMed ID: 24501543 [TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib: a new treatment option for myelofibrosis. Ganetsky A Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549 [TBL] [Abstract][Full Text] [Related]
5. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Tefferi A Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511 [TBL] [Abstract][Full Text] [Related]
6. Management of myelofibrosis after ruxolitinib failure. Harrison CN; Schaap N; Mesa RA Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525 [TBL] [Abstract][Full Text] [Related]
7. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Bryan JC; Verstovsek S Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614 [TBL] [Abstract][Full Text] [Related]
15. Novel therapeutics and targets in myelofibrosis. Waksal JA; Harrison CN; Mascarenhas JO Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713 [TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Mascarenhas J; Hoffman R Clin Cancer Res; 2012 Jun; 18(11):3008-14. PubMed ID: 22474318 [TBL] [Abstract][Full Text] [Related]
17. The new landscape of therapy for myelofibrosis. Gowin K; Emanuel R; Geyer H; Mesa RA Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258 [TBL] [Abstract][Full Text] [Related]
18. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Talpaz M; Kiladjian JJ Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323 [TBL] [Abstract][Full Text] [Related]
19. How I treat myelofibrosis. Cervantes F Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060 [TBL] [Abstract][Full Text] [Related]